Stockscreener 앱 받기
1.42
4.70%
-0.07
전일 마감가:
$1.49
열려 있는:
$1.49
하루 거래량:
3.37M
Relative Volume:
5.78
시가총액:
$37.75M
수익:
$50,000
순이익/손실:
$-41.60M
주가수익비율:
-0.838
EPS:
-1.6946
순현금흐름:
$-20.20M
1주 성능:
-2.07%
1개월 성능:
-0.70%
6개월 성능:
-17.92%
1년 성능:
-77.39%
1일 변동 폭
$1.42
$1.59
1주일 범위
$1.30
$1.59
52주 변동 폭
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.42 | 37.75M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-01 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-21 | 개시 | Alliance Global Partners | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-22 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-01 | 개시 | Robert W. Baird | Outperform |
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB) - TradingView
INMB Forecast — Price Target — Prediction for 2027 - TradingView
INMB Secures UK Regulatory Approval for Pediatric Treatment Plan - GuruFocus
INmune Bio receives UK regulatory approval for RDEB treatment plan - Investing.com
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - The Manila Times
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Advances Ebstrocel Toward UK Conditional Approval - TipRanks
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
INMB Receives Regulatory Guidance for CORDStrom in Epidermolysis Bullosa - GuruFocus
INmune Bio receives MHRA alignment for RDEB therapy filing - Investing.com
INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application - marketscreener.com
INmune Bio receives MHRA alignment for RDEB therapy filing By Investing.com - Investing.com Canada
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - The Manila Times
INmune Bio wins MHRA backing for 2026 UK rare-disease filing - Stock Titan
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inmune Bio focuses on Alzheimer’s data, shares on NASDAQ in a volatile biotech niche - Ad-hoc-news.de
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform - BioInformant
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan - TipRanks
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
INMB Q4 2025 Earnings: EPS Surprise of 24.6% Highlights Operational ProgressNon-GAAP Earnings - newsline.com
INMB Q4 2025 Earnings: EPS Beat Surprises Street as Clinical Pipeline AdvancesTax Rate Impact - newsline.com
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio reports positive Phase 2 MRI results - TipRanks
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
INMB: INmune Bio Reports Promising MRI Findings from Alzheimer's Trial - GuruFocus
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 MINDFuL Alzheimer's Trial - marketscreener.com
INmune Bio reports positive MRI results from Alzheimer’s trial - Investing.com
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial - TradingView
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - The Manila Times
Brain scans in early Alzheimer’s trial show drug affecting white matter - Stock Titan
INmune Bio (INMB) Q4 2025 Earnings Transcript - The Globe and Mail
INmune Bio (INMB) Holds Near Support Amid Modest Decline – Key Levels in FocusAAII Bearish - newsline.com
Inmune Bio Inc stock (US45764T1060): Short interest rose in May - AD HOC NEWS
INMB Q4 2025 Earnings: EPS Beat Surprises as Clinical-Stage Biotech Advances PipelineConsensus Miss Rate - The Legal Advocate
INmune Bio Inc. (INMB) Slips Further as Stock Tests Key Support at $1.35BPI Reversal - The Legal Advocate
INmune Bio Inc. (INMB) Holds Near Support as Biotech Stock Edges HigherTake Profit Levels - newsline.com
INMB Q4 2025 Earnings: Narrower Loss Beats Estimates, Pipeline Progress HighlightedWeak Earnings Momentum - The Legal Advocate
INMB Q4 2025 Earnings: EPS Surpasses Estimates as Loss NarrowsEarnings Stability Report - thelegaladvocate.com
INMB Q4 2025 Earnings: Narrowing Losses Amid Clinical Pipeline ProgressInterim Report - newsline.com
Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline - AD HOC NEWS
INMB Stock Price, Quote & Chart | INMUNE BIO INC (NASDAQ:INMB) - ChartMill
INmune Bio (INMB) Crushes Q4 2025 Estimates — EPS $-0.20 Tops ViewsBanking Earnings Report - The Legal Advocate
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform - marketscreener.com
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
자본화:
|
볼륨(24시간):